Swain, S. M., Tang, G., Lucas, P. C., Robidoux, A., Goerlitz, D., Harris, B. T., . . . Wolmark, N. (2019). Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination. Breast Cancer Res Treat.
Chicago-stil citatSwain, Sandra M., et al. "Pathologic Complete Response and Outcomes By Intrinsic Subtypes in NSABP B-41, a Randomized Neoadjuvant Trial of Chemotherapy With Trastuzumab, Lapatinib, or the Combination." Breast Cancer Res Treat 2019.
MLA-referensSwain, Sandra M., et al. "Pathologic Complete Response and Outcomes By Intrinsic Subtypes in NSABP B-41, a Randomized Neoadjuvant Trial of Chemotherapy With Trastuzumab, Lapatinib, or the Combination." Breast Cancer Res Treat 2019.